Better
Treatments,
More Tomorrows
Better
Treatments,
More Tomorrows
We Are
Advancing
a growing pipeline of product candidates for the treatment of highly resistant cancers and viruses.
Innovative
Therapies
through the use of proprietary technologies and data to develop a next generation anthracycline, immune/transcription modulators (STAT3 inhibitors) and metabolism/glycosylation inhibitors.
Innovative
Therapies
through the use of proprietary technologies and data to develop a next generation anthracycline, immune/transcription modulators (STAT3 inhibitors) and metabolism/glycosylation inhibitors.
Priority Development Pipeline
Latest Releases
Stock Information
NASDAQ: MBRX
NASDAQ: MBRX
Corporate
Presentation
Corporate
Presentation